Netherlands · Funded startup

Who invested in Sapreme Technologies

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$7.7Mraised across 1 round since 2019, from 1 source

Latest round
Grant, $7.7MFeb 2019
Investors
1
See who backed them

The rounds

  1. Feb 2019
    Grant$7.7M

    Reported by FinSMEs

Founders and team

From Sapreme Technologies's own website: 1 founder, 4 on the team.

Ruben PostelCSO & Founder
  • Marco TimmersCEO
  • Chris HuiskampCFO
  • Jeanne BolgerChair
  • Vp CmcBoard of Directors

AdvisersHendrik Zonnenberg

Everyone who backed them

Horizon 2020VC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Sapreme Technologies as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Aglaia Oncology FundVC firmPer its own site

Quick answers about Sapreme Technologies

Who invested in Sapreme Technologies?

Sapreme Technologies's investors include Horizon 2020.

How much has Sapreme Technologies raised?

Sapreme Technologies has raised $7.7M across 1 round since 2019.

When did Sapreme Technologies last raise?

Sapreme Technologies's most recent round was a Grant of $7.7M in Feb 2019.

What was Sapreme Technologies's biggest round?

Its most recent round, $7.7M in Feb 2019, is also its largest on record.

Who backed Sapreme Technologies first?

Sapreme Technologies's first round on record, in Feb 2019, was backed by Horizon 2020.

What stage is Sapreme Technologies at?

Sapreme Technologies's latest named round is a Grant, in Feb 2019.

Where is Sapreme Technologies based?

Sapreme Technologies is based in the Netherlands.

Companies like Sapreme Technologies

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.